A Study Comparing Clinical Outcomes of Erlotinib Versus Gefitinib in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients with Brain Metastasis

Trial Profile

A Study Comparing Clinical Outcomes of Erlotinib Versus Gefitinib in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients with Brain Metastasis

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Erlotinib (Primary) ; Gefitinib (Primary)
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Jul 2017 New trial record
    • 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top